Grading system for breast cancer

Anticancer Research

Volumn 18, Issue 3 C, 1998, Pages 2139-2144

  Schauer, A ^a   Korabiowska, M ^a   Kellner, S ^a   Schumacher, M ^b   Sauer, R ^c   Bojar, H ^d   Rauschecker, H ^e  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e Surgeon Rosenheim ^*  (Germany)

Author keywords

Auer scheme; Breast cancer; Grading system; Photometric analysis; Ploidy status; Proliferation antibody Ki67 (MiBI); S phase evalution

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOSIS RATE; PLOIDY; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR GROWTH;

ADULT; AGED; BREAST NEOPLASMS; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PHOTOMETRY; PLOIDIES;

EID: 0031880562     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Schauer A, Weiß A: Bedeutung des Tumorgrading und der Blutgefässeinbrüche für die Verlaufsbeurteilung des Mammacarcinoms bei Stadium I-Patientinnen. Verh Dt Ges Path 65: 382, 1981.
2. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I The value of histological grade in breast cancer: Experience from a large study with long term follow up. Histopathology 19: 403-410, 1991.
3. Schumacher M, Schmoor C, Sauerbrei W, Schauer A, Ummenhofer L, Gatzemeier W, Rauschecker H: The prognostic effect of histological tumor grade in node negative breast cancer patients. Breast Cancer Res Treat 25: 235-245, 1993.
4. Beerman H, Smit VT, Kluin PM, Bonzing BA, Hermans J, Cornelisse CJ: Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 12: 155-156, 1991.
5. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W: BCI2 protein expression in breast cancer in relation to established prognostic factors and other clinical pathological variables. Annals of Oncol 16: 1005-1010, 1995.
6. Schauer A, Rothe H, Balzer I, Bergholz M, Brehler R, Fiebig I, Rauschecker H, Nagel G, Blossey HC, Weber K, Osborn M, Aus HM, Harms H, Sauer R, Scheurlen H, Schumacher M: Monoclonal antibodies for improved evaluation of breast cancer prognosis In: Breast Cancer Scientific and Clinical Progress. Proc. of the Int. Assoc for Breast Cancer Res, Kluwer 1988.
7. Schauer A: Pathology of Invasive Breast Cancer. In: Bohmert H, Leis HP and Jackson IT (eds.): Breast Cancer. Conservative and Reconstructive Surgery. Thieme Verlag, Stuttgart, New York 10-18, 1989.
8. Schauer A, Marx D, Lipp I, Schumacher M, Sauerbrei W, Rauschecker H, Sauer R: Diagnostic tools and prognostic factors in human breast cancer evaluated by morphological and immunohistochemical methods. Proceedings of Int. Assoc for Breast Cancer Research Kluwer 1991 Ed. by L Dogliotti A Sapino G Bussolati
9. Sauer R, Schauer A, Rauschecker H, Galzemeier W, Sauerbrei W, Dunst Y, Seegenschmidt MH, Marx D: Breast preservation versus mastectomy in early breast cancer: 1991 update of the GBSG 1 protocol and prognostic factors Strahlenth. Oncol 168: 191-201, 1992.
10. Bloom HJS, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957.
11. Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM, Patchefsky AS, Penner DW, Pickren J, Roth JA, Schinella RA, Schwartz IS and Wheeler JE: Interobserver reproducibility of histopathological features in stage II breast cancer. Breast Cancer Res Treat 5: 3-10, 1985.
12. Dalton LW, Page DL and Dupont WD: Histologic grading of breast carcinoma: A reproducibility study. Cancer 73: 2765-2770, 1994.
13. Frierson HF, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC and Wilbur DC: Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am-J Clin Pathol 103: 195-198, 1995.
14. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I and Elston C: Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26: 873-879, 1995.
15. Rothe H, Schauer A, Rauschecker H: Immunohistochemische Bestimmung des proliferationsactiven Compartments beim Mammacarcinom Verh Dt, Ges Path 71, 355, 1987.
16. Rothe H, Brehles R, Balzer I, Schauer A: Proliferationsactivitäten in Mammacarcinomen. Immunohistochemische Unter suchungen mitdem monoklonalen Anti Körper Ki 67 Enke Verlag Stuttgart 1-5 1989.
17. Raillo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L and Smitten K: Prognostic value of Ki67 immunolabelling in primary operable breast cancer. Br. J. Cancer 68: 579-583, 1993.
18. 1 node negative breast cancer. Acta Oncol 36: 369-374, 1997.
19. Silvestrini R, Daidone MG and Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982-1987, 1985.
20. Parwaresch R: Personal communication
21. Auer GU, Caspersson TO, Wallgren AS: DNA-content and survival in mammary carcinoma. Analyt Quant Cytol 3: 161-165, 1980.
22. Clark GN, Dressler LG, Owens MA, Pounds G, Oldaker T and McGuire WL: Prediction of relapse or survival in patients with node negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989.
23. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T and Merkel D: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482-485, 1993.
24. Stal O, Skoog L, Rutquist LE, Carstensen JM, Wingrcn S, Sullivan S, Andersson C, Dufmats M, Nordenskjöld B: S-Phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 70: 1258-1262, 1994.
25. Bocking A, Adler CP, Common HH, Hilgarth M, Granzen B, hS Auffermann W: Algorithm for a DNA-Cytophotometric diagnosis and grading of malignancy. Analyt Quant Cytol 6: 1-8,1984.
26. Theissig F, Dimmer V, Haroske G, Kunze KD, Meyer W: Use of nuclear image cytometry, histopathological grading and DNA cytometry to make breast cancer prognosis more objective. Anal Cell Pathol 3: 351-360, 1991.
27. Sharma S, Mihra MC, Kapur BM, Verma K, Nath I: The prognostic significance of ploid analysis in operable breast cancer. Cancer 68: 2612-2616, 1991.
28. Rosen AV: Aneuploidy as a prognostic factor in breast cancer. Med Oncol Tumor Pharmacother 6: 117-120, 1989.
29. Baak JP, Chin D, Bacus SS: Comparative long term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy and morphometric and clinical features in paraffim embedded invasive breast cancer. Lab Invest 6: 215-223, 1991.
30. Rosner D and Lane WW: Should all patients with node negative breast cancer receive adjuvant therapy? Identifying additional subsets of low risk patients who are highly curable by surgery alone. Cancer 68: 1482-1494, 1991.